Principal Financial Group Inc. Has $151.03 Million Stake in Bristol Myers Squibb Company (NYSE:BMY)

Principal Financial Group Inc. increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 1.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,476,248 shares of the biopharmaceutical company's stock after acquiring an additional 32,394 shares during the period. Principal Financial Group Inc. owned about 0.12% of Bristol Myers Squibb worth $151,026,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. King Wealth Management Group lifted its holdings in Bristol Myers Squibb by 2.6% during the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock worth $413,000 after buying an additional 182 shares in the last quarter. Thoroughbred Financial Services LLC lifted its holdings in Bristol Myers Squibb by 1.1% during the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after buying an additional 190 shares in the last quarter. Marcum Wealth LLC lifted its holdings in Bristol Myers Squibb by 1.0% during the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after buying an additional 193 shares in the last quarter. Chatham Capital Group Inc. lifted its holdings in Bristol Myers Squibb by 0.9% during the 4th quarter. Chatham Capital Group Inc. now owns 21,795 shares of the biopharmaceutical company's stock worth $1,233,000 after buying an additional 200 shares in the last quarter. Finally, Leelyn Smith LLC lifted its holdings in Bristol Myers Squibb by 0.5% during the 4th quarter. Leelyn Smith LLC now owns 47,699 shares of the biopharmaceutical company's stock worth $2,698,000 after buying an additional 215 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock traded down $0.62 during midday trading on Friday, reaching $47.02. 7,024,133 shares of the company's stock were exchanged, compared to its average volume of 12,882,799. Bristol Myers Squibb Company has a 52 week low of $39.50 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The firm has a market cap of $95.68 billion, a price-to-earnings ratio of 17.61, a P/E/G ratio of 1.39 and a beta of 0.36. The stock's 50-day simple moving average is $47.73 and its 200 day simple moving average is $53.60.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter last year, the company posted ($4.40) earnings per share. Bristol Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. On average, analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.27%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is presently 92.88%.

Insider Activity

In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The stock was bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president owned 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.09% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. UBS Group reduced their price target on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Piper Sandler assumed coverage on Bristol Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target on the stock. Wall Street Zen lowered Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $55.00 price target (down from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and an average target price of $58.00.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.